DK1818408T3 - Rekombinant adenovirus af serotypen Ad11 - Google Patents

Rekombinant adenovirus af serotypen Ad11

Info

Publication number
DK1818408T3
DK1818408T3 DK07106036.2T DK07106036T DK1818408T3 DK 1818408 T3 DK1818408 T3 DK 1818408T3 DK 07106036 T DK07106036 T DK 07106036T DK 1818408 T3 DK1818408 T3 DK 1818408T3
Authority
DK
Denmark
Prior art keywords
serotypes
adenovirus
tropism
proteins
natural
Prior art date
Application number
DK07106036.2T
Other languages
English (en)
Inventor
Ronald Vogels
Abraham Bout
Menzo Jans Emko Havenga
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1818408(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1818408T3 publication Critical patent/DK1818408T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07106036.2T 1999-05-17 2000-05-16 Rekombinant adenovirus af serotypen Ad11 DK1818408T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17
EP04077434A EP1550722B1 (en) 1999-05-17 2000-05-16 Recombinant human adenovirus serotype 35

Publications (1)

Publication Number Publication Date
DK1818408T3 true DK1818408T3 (da) 2011-10-17

Family

ID=8240209

Family Applications (6)

Application Number Title Priority Date Filing Date
DK07106054.5T DK1816205T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus på grundlag af serotypen Ad48
DK07106044.6T DK1816204T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af Ad26-serotypen
DK07106036.2T DK1818408T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af serotypen Ad11
DK05077719T DK1681353T3 (da) 1999-05-17 2000-05-16 Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK04077434T DK1550722T3 (da) 1999-05-17 2000-05-16 Rekombinant human adenovirus serotype 35
DK00201738.2T DK1054064T4 (da) 1999-05-17 2000-05-16 Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK07106054.5T DK1816205T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus på grundlag af serotypen Ad48
DK07106044.6T DK1816204T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af Ad26-serotypen

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK05077719T DK1681353T3 (da) 1999-05-17 2000-05-16 Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK04077434T DK1550722T3 (da) 1999-05-17 2000-05-16 Rekombinant human adenovirus serotype 35
DK00201738.2T DK1054064T4 (da) 1999-05-17 2000-05-16 Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35

Country Status (14)

Country Link
EP (6) EP1816205B1 (da)
JP (2) JP4843145B2 (da)
KR (1) KR100741247B1 (da)
AT (6) ATE278792T1 (da)
AU (1) AU777041B2 (da)
CA (1) CA2372655C (da)
CY (4) CY1106762T1 (da)
DE (4) DE60043126D1 (da)
DK (6) DK1816205T3 (da)
ES (5) ES2289426T3 (da)
IL (3) IL146479A0 (da)
NZ (1) NZ515582A (da)
PT (5) PT1818408E (da)
WO (1) WO2000070071A1 (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
IL164802A0 (en) * 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
IL164803A0 (en) * 2002-04-25 2005-12-18 Crucell Holland Bv Means and methods for the production of adenovirusvectors
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005010149A2 (en) * 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
CN1972958B (zh) * 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
CN104263703B9 (zh) 2004-05-26 2019-12-17 普西奥克瑟斯医疗有限公司 用于治疗癌症的嵌合腺病毒
WO2006040330A2 (en) 2004-10-13 2006-04-20 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
ATE463559T1 (de) 2005-07-22 2010-04-15 Crucell Holland Bv Zelllinie zur produktion von coronaviren
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US9476061B2 (en) 2012-05-24 2016-10-25 Janssen Vaccines & Prevention B.V. Adenoviral vectors for transduction of vascular tissue
EP2872172B1 (en) 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP2920313B1 (en) 2012-11-16 2019-06-12 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
SI2988780T1 (sl) 2013-04-25 2019-05-31 Janssen Vaccines & Prevention B.V. Stabilizirani topni prefuzijski RSV F polipeptidi
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EA035504B1 (ru) 2014-09-03 2020-06-25 Бавариан Нордик А/С Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
BR112017004202A2 (pt) 2014-09-03 2019-09-03 Bavarian Nordic As composições para intensificar respostas imunes e seus usos
KR101971808B1 (ko) 2014-09-26 2019-04-23 베쓰 이스라엘 디코니스 메디칼 센터 인크 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
SI3215187T1 (sl) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention B.V. Terapevtska cepiva HPV16
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
CN107690479B (zh) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 编码b7蛋白质的溶瘤腺病毒
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
DK3319633T3 (da) 2015-07-07 2021-02-01 Janssen Vaccines & Prevention Bv Vaccine mod rsv
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
MA47522B1 (fr) 2015-12-15 2021-11-30 Janssen Vaccines & Prevention Bv Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MX2018007249A (es) 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102491447B1 (ko) 2016-04-05 2023-01-20 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CA3018941A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
CA3021341A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MX2018015361A (es) 2016-06-16 2019-03-11 Janssen Vaccines & Prevention Bv Formulacion de vacuna contra el vih.
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
US10925955B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a Marburg virus infection
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
MX2019009316A (es) 2017-02-09 2019-09-19 Janssen Vaccines & Prevention Bv Promotor corto y potente para la expresion de genes heterologos.
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
US10864263B2 (en) 2017-11-20 2020-12-15 Janssen Pharmaceuticals, Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. RECOMBINANT ADENOVIRUS AND THEIR USES
KR20200100745A (ko) 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
CN112437684A (zh) 2018-07-20 2021-03-02 扬森疫苗与预防公司 以提高的生产率表达寨卡抗原的重组腺病毒载体
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
KR20220008875A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
EP3969045A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JOP20220116A1 (ar) 2019-11-18 2023-01-30 Janssen Biotech Inc اللقاحات المستندة إلى الطافر calr وjak2 واستخداماتها
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022008613A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
US20220194999A1 (en) 2020-12-23 2022-06-23 Janssen Biotech, Inc. Neoantigen Peptide Mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
DE60039683D1 (de) * 1999-03-04 2008-09-11 Crucell Holland Bv Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections

Also Published As

Publication number Publication date
DE60035229T2 (de) 2008-02-21
ATE519854T1 (de) 2011-08-15
ATE278792T1 (de) 2004-10-15
DK1550722T3 (da) 2007-10-08
KR100741247B1 (ko) 2007-07-19
ATE364707T1 (de) 2007-07-15
WO2000070071A1 (en) 2000-11-23
CY1106762T1 (el) 2012-05-23
EP1550722B1 (en) 2007-06-13
JP5335037B2 (ja) 2013-11-06
EP1816204A1 (en) 2007-08-08
DE60014489T3 (de) 2010-08-12
KR20020028879A (ko) 2002-04-17
ATE485382T1 (de) 2010-11-15
IL214413A0 (en) 2011-09-27
CA2372655A1 (en) 2000-11-23
DE60014489D1 (de) 2004-11-11
PT1550722E (pt) 2007-09-25
EP1816205B1 (en) 2011-08-10
ES2231103T5 (es) 2010-04-15
EP1054064B1 (en) 2004-10-06
ES2372823T3 (es) 2012-01-26
ES2289426T3 (es) 2008-02-01
IL214413A (en) 2014-04-30
EP1681353B1 (en) 2009-10-07
ES2231103T3 (es) 2005-05-16
DK1816205T3 (da) 2011-11-21
EP1816205A1 (en) 2007-08-08
EP1818408A1 (en) 2007-08-15
IL146479A (en) 2011-12-29
CY1112008T1 (el) 2015-11-04
PT1054064E (pt) 2005-02-28
DK1681353T3 (da) 2010-01-04
IL146479A0 (en) 2002-07-25
ATE445018T1 (de) 2009-10-15
NZ515582A (en) 2003-11-28
EP1054064A1 (en) 2000-11-22
CY1112189T1 (el) 2015-12-09
DK1054064T3 (da) 2005-01-10
DK1816204T3 (da) 2011-01-24
PT1818408E (pt) 2011-11-15
AU4954700A (en) 2000-12-05
PT1816204E (pt) 2011-01-24
PT1816205E (pt) 2011-11-15
ES2354578T3 (es) 2011-03-16
JP2002543846A (ja) 2002-12-24
JP2011224014A (ja) 2011-11-10
CA2372655C (en) 2011-11-15
ES2372824T3 (es) 2012-01-26
DE60035229D1 (de) 2007-07-26
EP1550722A1 (en) 2005-07-06
DK1054064T4 (da) 2010-05-03
DE60014489T2 (de) 2005-11-24
CY1111494T1 (el) 2015-08-05
JP4843145B2 (ja) 2011-12-21
DE60045138D1 (de) 2010-12-02
DE60043126D1 (de) 2009-11-19
AU777041B2 (en) 2004-09-30
EP1818408B1 (en) 2011-08-10
EP1681353A1 (en) 2006-07-19
EP1054064B2 (en) 2009-12-16
ATE519855T1 (de) 2011-08-15
EP1816204B1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
DK1818408T3 (da) Rekombinant adenovirus af serotypen Ad11
NZ336829A (en) Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
LT2003107A (en) Pulmonary adminstration of chemically modified insulin
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
EP0648271A4 (en) ADENOVIRUS AGENTAL TRANSFER TO THE GASTROINTESTINAL TRACT.
JP2002537816A5 (da)
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
JP2008508899A5 (da)
Reed et al. The role of diffusion processes in fertility change in developing countries: report of a workshop
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
EP1270586A3 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
DK1224310T3 (da) Fremstilling af rekombinante adenovira og adenovirale banker
AU4403900A (en) Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
AU2001284511A1 (en) Impartment of virus-resistance with the use of plant protein binding to plant virus transport protein
Itoh et al. Two new phenolic glycosides from Alangium chinense
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
Cook et al. A Winter’s Tale
Chul-Sa et al. 14-DeoxyparsonsianidineN-Oxide: A Pyrrolidine Alkaloid Sequestered by the Giant Danaine Butterfly, Idea leuconoe
Tetsuo et al. Royal Jelly fromApis cerana japonicaandApis mellifera
Honami et al. Involvement of Ovotransferrin in the Thermally Induced Gelation of Egg White at around 65℃
DE29514303U1 (de) Zerlegbarer Flachdrachen für Spiel-, Sport- und Werbezwecke
CN101664597A (zh) 折叠式棋盘
IT1316976B1 (it) Procedimento per la produzione di manufatti ceramici sottoposti ataglio ed aventi basso contenuto di umidita'.